UBS Group’s MGC Diagnostics Corporation MGCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-2,418
Closed -$27K 8549
2017
Q4
$27K Buy
+2,418
New +$23.3K ﹤0.01% 6345
2017
Q3
Sell
-775
Closed -$6K 8258
2017
Q2
$6K Sell
775
-23
-3% -$189 ﹤0.01% 7082
2017
Q1
$7K Buy
+798
New +$7.04K ﹤0.01% 6863
2016
Q4
Sell
-1,776
Closed -$12K 8294
2016
Q3
$12K Sell
1,776
-592
-25% -$4.09K ﹤0.01% 6691
2016
Q2
$15K Sell
2,368
-1,781
-43% -$10.6K ﹤0.01% 6541
2016
Q1
$25K Buy
+4,149
New +$27.3K ﹤0.01% 6048
2015
Q4
Sell
-40
Closed 8748
2015
Q3
$0 Sell
40
-1,118
-97% -$6.37K ﹤0.01% 8857
2015
Q2
$7K Sell
1,158
-204
-15% -$1.27K ﹤0.01% 7735
2015
Q1
$10K Buy
1,362
+496
+57% +$3.45K ﹤0.01% 7668
2014
Q4
$6K Buy
+866
New +$5.65K ﹤0.01% 8896

UBS Group's MGCD Position: Q1 2018 in Review

UBS Group sold out of MGC Diagnostics Corporation (MGCD) in Q1 2018, closing a stake of 2,418 shares — an estimated $27K sold.

UBS Group first reported a position in MGCD in Q4 2014 and held it in 10 quarters. The position peaked at $27K in Q4 2017. 0 funds tracked by Wall St. Rank hold MGCD as of Q1 2018.

  • UBS Group reported no remaining MGC Diagnostics Corporation position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 2,418 MGC Diagnostics Corporation shares in Q1 2018, an estimated $27K.
  • UBS Group first reported a position in MGC Diagnostics Corporation in Q4 2014 and held it in 10 quarters.
  • UBS Group's MGC Diagnostics Corporation position peaked at $27K in Q4 2017.
  • 0 funds tracked by Wall St. Rank held MGC Diagnostics Corporation as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.